Cost-effectiveness of the tubeless automated insulin delivery system vs standard of care in the management of type 1 diabetes in the United States.
Sign Up to like & getrecommendations! Published in 2023 at "Journal of managed care & specialty pharmacy"
DOI: 10.18553/jmcp.2023.22331
Abstract: BACKGROUND: A tubeless, on-body automated insulin delivery (AID) system (Omnipod 5 Automated Insulin Delivery System) demonstrated improved glycated hemoglobin A1c levels and increased time in range (70 mg/dL to 180 mg/dL) for both adults and… read more here.
Keywords: system; tubeless; cost; tubeless aid ... See more keywords